Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]. There was no change in body mass index (39.9 +/- 1.4 vs. 40.2 +/- 1.4 kg/m2) or body fat distribution after treatment. Both the fasting (91 +/- 3 vs. 103 +/- 3 mg/dL; P < 0.001) and 2 h (146 +/- 8 vs. 171 +/- 6 mg/dL; P < 0.02) plasma glucose concentrations during the oral glucose tolerance test declined significantly. There was a concordant reduction in glycosylated hemoglobin to 5.7 +/- 0.1 from a pretreatment level of 6.1 +/- 0.1% (P < 0.03). Insulin sensitivity increased from 0.58 +/- 0.14 to 0.95 +/- 0.26 10(-5) min-1/pmol.L (P < 0.01) after treatment as did the disposition index (745 +/- 135 vs. 381 +/- 96; P < 0.05). The ability of the beta-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after troglitazone treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 +/- 1.1 from 4.3 +/- 0.8 (P < 0.05). Basal levels of total testosterone (109.3 +/- 15.2 vs. 79.4 +/- 9.8 ng/dL; P < 0.05) and free testosterone (33.3 +/- 4.0 vs. 21.2 +/- 2.6 pg/mL; P < 0.01) declined significantly after troglitazone treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently of any changes in gonadotropin levels. A decreased functional activity of PAI-1 in blood (from 12.7 +/- 2.8 to 6.3 +/- 1.4 AU/mL P < 0.05) was associated with a decreased concentration of PAI-1 protein (from 64.9 +/- 9.1 to 44.8 +/- 6.1 ng/mL; P < 0.05). No change in the functional activity of tissue plasminogen activator (from 5.3 +/- 0.4 to 5.1 +/- 0.5 IU/mL) was observed despite a decrease in its concentration (from 9.6 +/- 0.9 to 8.2 +/- 0.7 ng/mL; P < 0.05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects. We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. Troglitazone holds potential as a useful primary or adjunctive treatment for women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low SHBG levels are also increased by insulin-sensitising medication (Ehrmann et al., 1997;Moghetti et al., 2000;Moran et al., 2013);”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Ehrmann et al., 1997
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,981
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,199
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“It is important to note, however, that although insulin sensitivity improved in response to treatment, it remained profoundly depressed in these subjects and was disproportionate to the degree of obesity, as described previously ( 2 ).”
BackgroundBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 3×
“Because the product of these measures is presumed to be constant ( 33 , 42, 43), a compensatory decrease in AIRg would be expected to accompany the increase in Si observed after troglitazone treatment.”
BackgroundMethodInfluentialMazess, R., Barden, H., Bisek, J., & Hanson, J. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.6.1106 · Cited by 1,476
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 4×
“The product of Si and AIRg (disposition index) was also derived and provides a measure of b-cell secretory function adjusted for insulin sensitivity, previously described as a constant in any individual ( 43 ).”
BackgroundMethodInfluentialThiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053 · cited 1×
“Although the precise mechanism of action of troglitazone remains incompletely defined, it appears to enhance insulin action without directly stimulating insulin secretion ( 50 ) and acts as a selective ligand for the peroxisome proliferator-activated receptor-g (51).”
BackgroundToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Cited by
Items 101–200 of 485
Marca, A. L., Egbe, T. O., Morgante, G., Paglia, T., Ciani, A., & Leo, V. D. (2000) · Human Reproduction · doi:10.1093/humrep/15.1.21 · Cited by 119
The importance of insulin resistance in polycystic ovary syndrome
Goodarzi, M. O., & Korenman, S. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00734-9 · Cited by 130
Baillargeon, J., & Carpentier, A. C. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.12.055 · Cited by 131
Belli, S., Graffigna, M., Oneto, A., Otero, P., Schurman, L., & Levalle, O. A. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.08.024 · Cited by 127
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 125
The Metabolic Syndrome in Polycystic Ovary Syndrome
Essah, P. A., Wickham, E. P., & Nestler, J. E. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31802f3547 · Cited by 134
Rikitake, Y., & Liao, J. K. (2005) · Circulation · doi:10.1161/circulationaha.105.534024 · Cited by 118
Cardiovascular Risk In Women With Polycystic Ovary Syndrome
Talbott, E. O., Zborowski, J. V., Sutton-Tyrrell, K., McHugh-Pemu, K. P., & Guzick, D. S. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70189-3 · Cited by 126
Insulin-sensitizing agents in polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02156 · Cited by 119
Paradisi, G., Steinberg, H. O., Shepard, M. K., Brechtel, G., & Baron, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020386 · Cited by 120
Polycystic Ovary Syndrome and Obstructive Sleep Apnea
Tasali, E., Cauter, E. V., & Ehrmann, D. A. (2008) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2007.11.001 · Cited by 125
Self-citationElbein, S. C., Wegner, K., & Kahn, S. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.221 · Cited by 109
Cobin, R. H., Futterweit, W., Nestler, J. E., Reaven, G. M., Jellinger, P. S., Handelsman, Y., Redmond, G. P., & Thatcher, S. S. (2005) · Endocrine Practice · doi:10.4158/ep.11.2.125 · Cited by 117
TNF- and Hyperandrogenism: A Clinical, Biochemical, and Molecular Genetic Study
Escobar-Morreale, H. F., Calvo, R. M., Sancho, J., & Millán, J. L. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7770 · Cited by 121
Ünlühızarcı, K., Keleştimur, F., Bayram, F., Şahin, Y., & Tutuş, A. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00786.x · Cited by 113
Vasudevan, A. R., & Balasubramanyam, A. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2004.6.850 · Cited by 110
Pirwany, I. R., Yates, R. W. S., Cameron, I. T., & Fleming, R. (1999) · Human Reproduction · doi:10.1093/humrep/14.12.2963 · Cited by 100
Legro, R. S., Zaino, R. J., Demers, L. M., Kunselman, A. R., Gnatuk, C. L., Williams, N. I., & Dodson, W. C. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.12.025 · Cited by 107
Ehrmann, D. A., Tang, X. A., Yoshiuchi, I., Cox, N. J., & Bell, G. I. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020216 · Cited by 99
Self-citationAdipose tissue and reproduction in women
BOHLER, H. C. L., Mokshagundam, S. L., & Winters, S. J. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.03.079 · Cited by 110
Mechanisms by which Thiazolidinediones Enhance Insulin Action
Reginato, M. J., & Lazar, M. A. (1999) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(98)00110-6 · Cited by 93
Troglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Plosker, G. L., & Faulds, D. M. (1999) · Drugs · doi:10.2165/00003495-199957030-00014 · Cited by 104
Recent findings concerning thiazolidinediones in the treatment of diabetes
Boden, G. H., & Zhang, M. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.243 · Cited by 97
Tosi, F., Negri, C., Perrone, F., Dorizzi, R. M., Castello, R., Bonora, E., & Moghetti, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2939 · Cited by 92
Siebert, T. I., Kruger, T. F., Steyn, D. W., & Nosarka, S. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.06.014 · Cited by 102
Hara, M., Alcoser, S. Y., Qaadir, A., Beiswenger, K. K., Cox, N. J., & Ehrmann, D. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8255 · Cited by 89
Self-citationPathogenesis of polycystic ovary syndrome: what is the role of obesity?
Salehi, M., Bravo-Vera, R., Sheikh, A., Gouller, A., & Poretsky, L. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.005 · Cited by 107
Acne: Effect of Hormones on Pathogenesis and Management
Shaw, J. C. (2002) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200203080-00007 · Cited by 90
Endometrial Abnormality in Women With Polycystic Ovary Syndrome
Shang, K., Jia, X., Qiao, J., Kang, J., & Guan, Y. (2012) · Reproductive Sciences · doi:10.1177/1933719111430993 · Cited by 93
Tarkun, I., Çetinarslan, B., Türemen, E., Şahin, T., Cantürk, Z., & Komsuoğlu, B. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01948 · Cited by 89
Rautio, K., Tapanainen, J. S., Ruokonen, A., & Morin-Papunen, L. C. (2006) · Human Reproduction · doi:10.1093/humrep/dei505 · Cited by 88
Mitwally, M. F., Kuşçu, N. K., & Yalcinkaya, T. M. (1999) · Human Reproduction · doi:10.1093/humrep/14.11.2700 · Cited by 88
Aromatase inhibitors in ovulation induction
(2004) · Seminars in Reproductive Medicine · doi:10.1055/s-2004-823028 · Cited by 87
Kanaya, A. M., Fyr, C. W., Vittinghoff, E., Harris, T. B., Park, S. W., Goodpaster, B. H., Tylavsky, F., & Cummings, S. R. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.350 · Cited by 97
Schoppee, P. D., Garmey, J. C., & Veldhuis, J. D. (2002) · Biology of Reproduction · doi:10.1095/biolreprod66.1.190 · Cited by 92
Gasic, S., Bodenburg, Y., Nagamani, M., Green, A., & Urban, R. J. (1998) · Endocrinology · doi:10.1210/endo.139.12.6385 · Cited by 80
Cardiometabolic features of polycystic ovary syndrome
Hoffman, L., & Ehrmann, D. A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0755 · Cited by 95
Self-citationKernan, W. N., Inzucchi, S. E., Viscoli, C. M., Brass, L. M., Bravata, D. M., Shulman, G. I., McVeety, J. C., & Horwitz, R. I. (2003) · Stroke · doi:10.1161/01.str.0000071108.00234.0e · Cited by 84
Rosenfield, R. L., Mortensen, M., Wroblewski, K., Littlejohn, E., & Ehrmann, D. A. (2011) · Human Reproduction · doi:10.1093/humrep/der291 · Cited by 89
Self-citationTrost, S. U., Pratley, R. E., & Sobel, B. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0052-5 · Cited by 83
Self-citationOrtega-González, C., Cardoza, L., Coutiño, B., Hidalgo, R., Arteaga‐Troncoso, G., & Parra, A. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05844 · Cited by 82
Rouzi, A. A., & Ardawi, M. S. M. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.1312 · Cited by 88
Endocrine and Metabolic Effects of Rosiglitazone in Non-obese Women with Polycystic Ovary Disease
Dereli, D., Dereli, T., Bayraktar, F., Özgen, G., & Yılmaz, C. (2005) · Endocrine Journal · doi:10.1507/endocrj.52.299 · Cited by 92
Taylor, A. E. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70045-1 · Cited by 95
Polycystic ovary syndrome: A review for dermatologists
Housman, E., & Reynolds, R. V. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.007 · Cited by 95
Insulin-Lowering Drugs In Polycystic Ovary Syndrome
Iuorno, M. J., & Nestler, J. E. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70191-1 · Cited by 79
PAI-1 and diabetes: a journey from the bench to the bedside
Schneider, D. J., & Sobel, B. E. (2012) · Diabetes Care · doi:10.2337/dc12-0638 · Cited by 78
Self-citationPolycystic ovary syndrome and insulin-resistant hyperinsulinemia
Rosenfield, R. L. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.117430 · Cited by 91
Self-citationHamaguchi, E., Takamura, T., Shimizu, A., & Nagai, Y. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054346 · Cited by 78
CARDIOVASCULAR CONSEQUENCES OF POLYCYSTIC OVARY SYNDROME
Amowitz, L. L., & Sobel, B. E. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70079-7 · Cited by 77
Self-citationJesmin, S., Sakuma, I., Hattori, Y., & Kitabatake, A. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000094235.78783.d1 · Cited by 75
Polycystic Ovary Syndrome: Clinical Perspectives and Management
Futterweit, W. (1999) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199906000-00024 · Cited by 83
Patel, K. S., Coffler, M. S., Dahan, M. H., Malcom, P. J., Deutsch, R., & Chang, R. J. (2003) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01945.x · Cited by 74
Polycystic ovary syndrome: etiology and pathogenesis
Matalliotakis, I., Kourtis, A., Koukoura, O., & Panidis, D. (2006) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-006-0171-x · Cited by 87
Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes
Willi, S. M., Kennedy, A., Brant, B. P., Wallace, P., Rogers, N. L., & Garvey, W. T. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00127-4 · Cited by 77
Stadtmauer, L. A., Wong, B. C.-M., & Oehninger, S. (2002) · Human Reproduction · doi:10.1093/humrep/17.12.3016 · Cited by 78
Geller, D. H., Pacaud, D., Gordon, C. M., & Misra, M. (2011) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2011-9 · Cited by 78
Veldhuis, J. D., Zhang, G., & Garmey, J. C. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8308 · Cited by 72
Cataldo, N. A., Abbasi, F., McLaughlin, T. L., Basina, M., Fechner, P. Y., Giudice, L. C., & Reaven, G. M. (2006) · Human Reproduction · doi:10.1093/humrep/dei289 · Cited by 71
Thiazolidinediones ? some recent developments
Stümvoll, M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.7.1179 · Cited by 75
Ginsberg, H. N., Plutzky, J., & Sobel, B. E. (1999) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/204748739900600512 · Cited by 77
Self-citationGlintborg, D., Hermann, A. P., Andersen, M., Hagen, C., Beck‐Nielsen, H., Veldhuis, J. D., & Henriksen, J. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.12.067 · Cited by 73
Parker, J. C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00093-5 · Cited by 74
Zaman, A. K. M. T., Fujii, S., Sawa, H., Goto, D., Ishimori, N., Watano, K., Kaneko, T., Furumoto, T., Sugawara, T., Sakuma, I., et al. (2001) · Circulation · doi:10.1161/01.cir.103.25.3123 · Cited by 68
Self-citationEarly origins of polycystic ovary syndrome
Dumesic, D. A., Schramm, R. D., & Abbott, D. H. (2005) · Reproduction Fertility and Development · doi:10.1071/rd04092 · Cited by 72
Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease
Fonseca, V. A. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00616-7 · Cited by 71
Liu, S., & Sun, Q. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12517 · Cited by 68
Samad, F., Pandey, M., Bell, P. A., & Loskutoff, D. J. (2000) · Molecular Medicine · doi:10.1007/bf03402048 · Cited by 70
Kelly, C. J. G., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J., Rumley, A., Lowe, G. D. O., & Sattar, N. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8634 · Cited by 72
Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)
Froment, P., & Touraine, P. A. (2006) · PPAR Research · doi:10.1155/ppar/2006/73986 · Cited by 68
Platelet function, coagulopathy, and impaired fibrinolysis in diabetes
Sobel, B. E., & Schneider, D. J. (2004) · Cardiology Clinics · doi:10.1016/j.ccl.2004.06.009 · Cited by 69
Self-citationSharma, S. T., & Nestler, J. E. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.02.003 · Cited by 70
Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan
Kubota, T. (2013) · Reproductive Medicine and Biology · doi:10.1007/s12522-013-0145-1 · Cited by 66
Hahn, S., Fingerhut, A., Khomtsiv, U., Khomtsiv, L., Tan, S., Quadbeck, B., Herrmann, B. L., Knebel, B., Müller‐Wieland, D., Mann, K., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02261.x · Cited by 63
Treatment of polycystic ovary syndrome with insulin-lowering agents
Wang, P., Streicher, P., & Glueck, C. J. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.8.1177 · Cited by 63
Carmassi, F., Negri, F. D., Fioriti, R., Giorgi, A. D., Giannarelli, C., Fruzzetti, F., Pedrinelli, R., Dell’Omo, G., & Bersi, C. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2004.11.026 · Cited by 62
Puberty and polycystic ovary syndrome
Witchel, S. F. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.04.028 · Cited by 67
Lemay, A., Dodin, S., Turcot, L., Déchêne, F., & Forest, J.-C. (2006) · Human Reproduction · doi:10.1093/humrep/dei312 · Cited by 61
Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias, J. P., Yu, J. G., Kruszynska, Y. T., & Olefsky, J. M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.64 · Cited by 61
Patel, K., Coffler, M. S., Dahan, M. H., Yoo, R. Y., Lawson, M. A., Malcom, P. J., & Chang, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030816 · Cited by 60
Insulin resistance in patients with polycystic ovary syndrome
Schröder, A. K., Tauchert, S., Ortmann, O., Diedrich, K., & Weiss, J. M. (2004) · Annals of Medicine · doi:10.1080/07853890410035296 · Cited by 65
Glueck, C. J., Sieve, L., Zhu, B., & Wang, P. (2006) · Metabolism · doi:10.1016/j.metabol.2005.09.008 · Cited by 60
Polycystic ovary syndrome: a risk factor for cardiovascular disease?
Rajkhowa, M., Glass, M. R., Rutherford, A. J., Michelmore, K., & Balen, A. H. (2000) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2000.tb11572.x · Cited by 64
Polycystic ovarian syndrome (PCOS) and insulin resistance
Park, K. H., Kim, J. Y., Ahn, C. W., Song, Y. D., Lim, S.-K., & Lee, H. C. (2001) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(01)00442-8 · Cited by 67
Peroxisome proliferator-activated receptors in endothelial cell biology
Plutzky, J. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200110000-00006 · Cited by 60
Acceleration of Restenosis by Diabetes: Pathogenetic Implications
Sobel, B. E. (2001) · Circulation · doi:10.1161/01.cir.103.9.1185 · Cited by 64
Self-citationPPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility
Minge, C. E., Robker, R. L., & Norman, R. J. (2008) · PPAR Research · doi:10.1155/2008/243791 · Cited by 60
PCOS: an ovarian disorder that leads to dysregulation in the hypothalamic–pituitary–adrenal axis?
Doi, S. A. R., Towers, P. A., Scott, C., & Al-Shoumer, K. A. S. (2004) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2004.06.024 · Cited by 67
The Role of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome
Katsiki, N., Georgiadou, E., & Hatzitolios, A. I. (2009) · Drugs · doi:10.2165/00003495-200969110-00001 · Cited by 57
Irregular cycles and steroid hormones in polycystic ovary syndrome
Doi, S. A. R., Al-Zaid, M. M., Towers, P. A., Scott, C., & Al-Shoumer, K. A. S. (2005) · Human Reproduction · doi:10.1093/humrep/dei093 · Cited by 56
Insulin Release in Impaired Glucose Tolerance
Breda, E., TOFFOLO, G. M., Polonsky, K. S., & Cobelli, C. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s227 · Cited by 62
Self-citationTREATMENT OF TYPE 2 DIABETES MELLITUS
Feinglos, M. N., & Bethel, M. A. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70023-7 · Cited by 56
Lemieux, S., Lewis, G. F., Ben-Chetrit, A., Steiner, G., & Greenblatt, E. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6140 · Cited by 54
Shobokshi, A., & Shaarawy, M. (2003) · Journal of the Society for Gynecologic Investigation · doi:10.1016/s1071-5576(02)00260-5 · Cited by 60
An Approach to the Patient with Hirsutism
Loriaux, D. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2744 · Cited by 58
Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary
Gasic, S., Nagamani, M., Green, A., & Urban, R. J. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.111242 · Cited by 53
Marx, N., Libby, P., & Plutzky, J. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800404 · Cited by 61
Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women
Tosi, F., Negri, C., Brun, E., Castello, R., Faccini, G., Bonora, E., Muggeo, M., Toscano, V., & Moghetti, P. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0782 · Cited by 52
Hyperinsulinism and Its Interaction With Hyperandrogenism in Polycystic Ovary Syndrome
Sozen, I., & Arici, A. M. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200005000-00026 · Cited by 55
Polycystic Ovary Syndrome and Its Differential Diagnosis
Lane, D. E. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000197817.93201.04 · Cited by 59
Metadata
- Authors
- Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- University of Vermont (US)
- Corresponding author
- Ehrmann, David A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-07
- Volume
- 82
- Issue
- 7
- Pages
- 2108-2116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2073637312
- Cited by
- 461
- References
- 67
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 6 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 2 · 2014: 5 · 2013: 10 · 2012: 11
- FWCI
- 36.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- troglitazone, polycystic ovary syndrome, insulin resistance, insulin secretion, beta-cell function, ovarian steroidogenesis, fibrinolysis, plasminogen activator inhibitor-1, tissue plasminogen activator, hyperinsulinemia, impaired glucose tolerance, insulin sensitizers, hyperandrogenemia, obese women, leuprolide
- MeSH terms
- Troglitazone, Adult, Androgens, Chromans, Female, Fibrinolysis, Glucose, Glucose Tolerance Test, Gonadotropins, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Thiazoles, Leuprolide, Plasminogen Activator Inhibitor 1, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.